-+ 0.00%
-+ 0.00%
-+ 0.00%

Kalaris Therapeutics Q2 EPS $(0.61) Misses $(0.52) Estimate

Benzinga·08/13/2025 12:06:29
Listen to the news
Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.52) by 17.31 percent. This is a 85.68 percent increase over losses of $(4.26) per share from the same period last year.